Mirum Pharmaceuticals (MIRM) EBIT (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly EBIT of -$789.5 million for Q1 2026, down 5099.66% year-over-year from $15.8 million in Q1 2025, and down 17186.29% quarter-over-quarter from -$4.6 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) EBIT (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' EBIT history runs 8 years deep, the most recent figure standing at -$789.5 million for Q1 2026.
- In Q1 2026, EBIT fell 5099.66% year-over-year to -$789.5 million; the TTM figure through Mar 2026 stood at -$796.4 million (down 943.51% YoY), while the FY2025 annual figure was -$22.1 million, up 74.73% from the prior year.
- EBIT for Q1 2026 stood at -$789.5 million, down from -$4.6 million in the prior quarter.
- The five-year high for EBIT was $2.6 million in Q3 2025, with the low at -$789.5 million in Q1 2026.
- The 5-year median for EBIT is -$25.1 million (2023), against an average of -$67.0 million.
- The sharpest annual moves came in 2025 and 2026: EBIT surged 120.52% in 2025, then sank 5099.66% in 2026.
- Mirum Pharmaceuticals' EBIT stood at -$34.2 million in 2022, then grew by 4.61% to -$32.6 million in 2023, then gained by 25.67% to -$24.2 million in 2024, then surged by 81.15% to -$4.6 million in 2025, then tumbled by 17186.29% to -$789.5 million in 2026.
- Business Quant data shows MIRM's EBIT at -$789.5 million in Q1 2026, -$4.6 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | -42.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.54 Mn |
| Mar 31, 2026 | -789.47 Mn |
| Dec 31, 2025 | -4.57 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | -4.99 Mn |
| Mar 31, 2025 | -15.18 Mn |
| Dec 31, 2024 | -24.22 Mn |
| Sep 30, 2024 | -12.68 Mn |
| Jun 30, 2024 | -24.23 Mn |
| Mar 31, 2024 | -26.47 Mn |
| Dec 31, 2023 | -32.59 Mn |
| Sep 30, 2023 | -25.15 Mn |
| Jun 30, 2023 | -24.27 Mn |
| Mar 31, 2023 | -27.15 Mn |
| Dec 31, 2022 | -34.16 Mn |
| Sep 30, 2022 | -32.88 Mn |
| Jun 30, 2022 | -31.44 Mn |
| Mar 31, 2022 | -32.74 Mn |
| Dec 31, 2021 | -45.58 Mn |
| Sep 30, 2021 | -42.82 Mn |